Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Wasp venom offers hope for cancer patients
brazilian wasp
The wasp, native to Brazil, produces a venom containing a cancer-fighting ingredient.

Study shows how toxin selectively attacks cancer cells
 
Scientists say the venom of a Brazilian wasp may one day be used in the fight against cancer.

New research reveals for the first time how a toxin contained in the venom is able to attack cancer cells, leaving normal cells unharmed.

To protect itself from predators, the social wasp Polybia paulista produces a venom containing the toxin MP1 (Polybia-MP1).

Laboratory testing has shown the toxin can inhibit the growth of bladder and prostate cancer cells, as well as the multi-drug resistant leukaemic cells.

Until now it was not understood how MP1 is able to do this without damaging normal cells. But according to new research published in the Biophysical Journal, the toxin selectively attacks lipids that are abnormally distributed across the surface of cancer cells. In a matter of seconds, this creates gaping holes, allowing molecules that are vital for cell function to escape.

Co-author Dr Paul Beales from the University of Leeds said this approach to treatment would be "an entirely new class of anti-cancer drugs" and could help develop new combination therapies, where multiple drugs are used at the same time to attack different parts of the cancer cells.

In future, the researchers plan to alter the amino acid sequence of MP1 to find out more about the peptide's structure, increasing its potential for clinical purposes.

"Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine," Dr Beales explained.

"As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that."

Image © Prof. Mario Palma/Sao Paulo State University

Become a member or log in to add this story to your CPD history

Submissions open for BSAVA Clinical Research Abstracts 2026

News Story 1
 The BSAVA has opened submissions for the BSAVA Clinical Research Abstracts 2026.

It is an opportunity for applicants to present new research on any veterinary subject, such as the preliminary results of a study, discussion of a new technique or a description of an interesting case.

They must be based on high-quality clinical research conducted in industry, practice or academia, and summarised in 250 words.

Applications are welcome from vets, vet nurses, practice managers, and students.

Submissions are open until 6 March 2026. 

Click here for more...
News Shorts
Survey seeks ruminant sector views on antimicrobial stewardship

A new survey is seeking views of people working in the UK ruminant sector on how to tackle the challenge of demonstrating responsible antibiotic stewardship.

Forming part of a wider, collaborative initiative, the results will help identify the types of data available so that challenges with data collection can be better understood and addressed.

Anyone working in the UK farming sector, including vets and farmers,is encouraged to complete the survey, which is available at app.onlinesurveys.jisc.ac.uk